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MicroRNAs (miRNA) are a class of small non-coding RNAs that have recently emerged as
epigenetic modulators of gene expression in psychiatric diseases like schizophrenia and
major depression. So far, miRNAs have neither been studied in patients suffering from
posttraumatic stress disorder (PTSD) nor in PTSD animal models. Here, we present the
first study exploring the connection between miRNAs and PTSD. Employing our previously
established PTSD mouse model, we assessed miRNA profiles in prefrontal cortices (PFCs)
dissected from either fluoxetine or control-treated wildtype C57BL/6N mice 74 days after
their subjection to either a single traumatic electric footshock or mock-treatment. Fluoxe-
tine is an antidepressant known to be effective both in PTSD patients and in mice suffering
from a PTSD-like syndrome. Screening for differences in the relative expression levels of
all potential miRNA target sequences of miRBase 18.0 by pairwise comparison of the
PFC miRNA profiles of the four mouse groups mentioned resulted in identification of five
miRNA candidate molecules. Validation of these miRNA candidates by reverse transcrip-
tase quantitative polymerase chain reaction (RT-qPCR) revealed that the therapeutic action
of fluoxetine in shocked mice is associated with a significant reduction in mmu-miR-1971
expression. Furthermore, our findings suggest that traumatic stress and fluoxetine interact
to cause distinct alterations in the mouse PFC miRNA signature in the long-term.
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INTRODUCTION
Posttraumatic stress disorder (PTSD) is a debilitating anxiety
disease occurring in about 2–9% of individuals after their expo-
sure to life-threatening events like severe accidents, sexual abuse,
combat, or natural catastrophes (1, 2). Although selective sero-
tonin reuptake inhibitor (SSRIs) antidepressants like fluoxetine
are currently the first line choice in PTSD drug treatment (3,
4), the response rates to SSRI treatment rarely exceed 60% and
less than 20–30% of SSRI-treated PTSD patients achieve full
remission (5). This unsatisfactory situation together with the
fact that there is currently no drug available that specifically
tackles PTSD core symptoms (3, 5), namely re-experiencing of
traumatic memories, nervous hyperarousal, and avoidance of
trauma-related cues (6) stresses the urgent need for development
of novel PTSD-specific drugs and hence for elucidation of the,
as yet insufficiently explored, molecular basis of PTSD. Epige-
netic mechanisms increasingly emerge to play a role in PTSD
pathobiology (7), i.e., it was recently discovered that allele-specific
DNA demethylation of FKBP5, a potential PTSD biomarker (8),
mediates gene× childhood trauma interactions (9). Furthermore,
epigenetic regulation of immune-system associated molecules (10)
and of catechol-O-methyltransferase (COMT), an enzyme which
is critical for regulation of synaptic dopamine, was reported to
be altered in PTSD patients (11). Besides DNA methylation and
histone modifications, some authors consider small non-coding
RNAs, like the about 22 nucleotides (nt) long miRNAs, as epi-
genetic regulators (12, 13). However, the view of miRNAs as
regulators of epigenetic processes as well as reports on the epi-
genetic regulation of miRNA expression are more common (14,
15). miRNAs are well conserved in eukaryotic organisms (16) and
play a pivotal role in regulation of posttranscriptional gene expres-
sion (12). They are encoded by eukaryotic DNA and function via
base-pairing with complementary sequences of mRNA molecules
through rapid mRNA decay and direct translational repression
(17). MiRNAs have been associated not only with cancer (14) and
autoimmune diseases (18) but also with psychiatric disorders like
schizophrenia, autism (19), major depression (20), and anxiety
diseases like panic disorder and specific phobias (21). In mice,
expression of miR-128b was found to be increased in infralimbic
prefrontal cortices (PFCs) in response to fear extinction training
(22) which is considered to model exposure-based therapy (23),
a psychotherapeutic strategy applied inter alia in PTSD patients
(24). Furthermore, there is much evidence for miRNAs to play an
important role in relation to the epigenetic tuning of the stress
response (25, 26). For example, stress was shown to up-regulate
mi34c expression in mouse amygdala and, moreover, lentivirally
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overexpressed mi34c was reported to induce anxiolytic-like behav-
ior after challenge (27). Interestingly, to the best of our knowledge,
miRNA regulation, expression, and function have so far not been
studied at all in PTSD, neither in PTSD patients nor in PTSD
animal models. Here, we present the first study exploring the con-
nection between miRNAs and the PTSD-like syndrome in rodents.
Using a miRNA microarray, we analyzed miRNA profiles in our
previously established mouse model for PTSD (28, 42). In detail,
we compared miRBase 18.0 based miRNA profiles in PFC samples
of four groups of mice, i.e., footshocked and non-footshocked
mice which were either fluoxetine-treated or untreated. We chose
the PFC for miRNA profile analysis since this brain region was
found to be reduced in volume (30) as well as altered in func-
tion (31, 32) in PTSD patients. Moreover, since in the PTSD
model studied here we found shocked mice to exhibit an increased
conditioned fear response, the notion that the PFC, beyond its
known function in fear extinction (33), increasingly emerges to
play a role in fear conditioning (33, 34) further sparked our inter-
est in this brain region. In addition, prefrontal cortical miRNA
expression levels have been reported to be altered in other psychi-
atric disorders: for instance, let-7d was shown to be up-regulated
in the PFC of spontaneous hyperactive rats, an animal model
for attention deficit hyperactivity disorder (ADHD) (35), and
miR-195 was demonstrated to fine-tune regional levels of brain
derived neurotrophic factor (BDNF) in the PFC of schizophrenic
patients (36).
MATERIALS AND METHODS
ANIMALS
All experimental procedures were approved by the Committee on
Animal Health and Care of Upper Bavaria (Regierung von Ober-
bayern), Germany (approval ID-AZ: 55.2-1-54-2531-41-09) and
were conducted according to the current regulations for animal
experimentation in Germany and the European Union (European
Communities Council Directive 86/609/EEC). Twenty-three days
old male C57BL/6NCrl mice purchased from Charles River GmbH
(Sulzfeld, Germany) were housed in groups in the animal facility
of the Max Planck Institute (MPI-P) for 6 weeks under an inverse
12:12 h light-dark cycle (lights off: 09:00 a.m.) with food and water
ad libitum.
PTSD MOUSE MODEL
Experiments were performed during the activity phase of the mice,
i.e., between 9:30 a.m. and 6:00 p.m., employing our established
PTSD mouse model which we described in detail previously (28,
29). Briefly, 10-week-old male C57BL/6NCrl mice were subjected
to a single 1.5 mA electric footshock for 2 s or mock treatment
(exposure to shock chamber, the latter is termed “shock context”
or“shock chamber”in the following). Beginning the day after foot-
shock or mock treatment, half of the footshocked and half of the
mock-treated mice received oral fluoxetine treatment (n= 6 per
group). Thus, we compared four groups of mice, i.e., footshocked
and mock-treated mice, which were either fluoxetine (Ratio-
pharm, Ulm, Germany) or vehicle-treated; these groups are termed
“no-shock-vehicle,” “no-shock-fluoxetine,” “shock-vehicle,” and
“shock-fluoxetine” in the following. Fluoxetine was administered
in drinking water in a dose of 20 mg/kg/day for 28 days. The
control group received drinking water only. On day 28 after foot-
shock or mock treatment, fluoxetine efficacy was assessed by
evaluation of their generalized fear response for 60 s during the
presentation of a neutral tone (80 dB, 9 kHz) in a neutral context.
Subsequently, the dose of fluoxetine was halved (10 mg/kg/day)
and treatment was further continued for 3 days until discontinu-
ation on day 31. Then, 59–60 days after footshock or mock treat-
ment, hyperarousal was assessed by evaluation of their acoustic
startle response. In addition, their generalized fear response was
analyzed by monitoring their freezing behavior upon subsequent
exposure to a neutral experimental context and to an experimen-
tal context similar to the shock chamber. Finally, the conditioned
fear response of the mice was assessed by measuring their freezing
behavior during (re-)exposure to the shock chamber. Video-taped
animal behavior was rated off-line by a trained observer who was
blind to the experimental conditions. Statistical analysis of behav-
ioral data was performed using two-way ANOVA and Bonferroni
post hoc tests.
RNA EXTRACTION
Seventy four days after footshock or mock treatment, mice were
sacrificed by cervical dislocation and PFCs were dissected (n= 6
per group). Total RNA was extracted employing the TRIzol®
protocol following the manufacturer’s instructions (Invitrogen,
Paisley, UK). Extracted total RNA was resolved in nuclease free
water. Concentrations of total RNA were assessed spectropho-
tometrically with a Nanophotometer (Implen GmbH, Munich,
Germany). RNA integrity was assured by Agilent 2100 Bioana-
lyzer (Agilent Technologies, Inc., Santa Clara, CA, USA) both in
our laboratory and in the laboratory of the microarray service
provider (Exiqon A/S, Vedbaek, Denmark). RNA integrity num-
bers were≥8.90 throughout the samples and all samples exhibited
clear 18S and 28S RNA peaks in Bioanalyzer profiles.
miRCURY LNA™ miRNA MICROARRAY PROFILING
RNA samples (6× 4= 24 samples) were shipped from the MPI-P
in Munich to the microarray service provider Exiqon (Exiqon A/S,
Vedbaek, Denmark) where all miRNA microarray experiments
were performed. Accordingly, the chapter at hand (description
of miRNA microarray procedure) is based on information pro-
vided by Exiqon (Exiqon A/S, Vedbaek, Denmark): 600 ng of total
RNA extracted from samples were labeled with fluorescent Hy3™
and 600 ng of total RNA from reference probe with fluorescent
Hy5™ using the miRCURY LNA™ miRNA Hi-Power Labeling Kit
(Exiqon A/S, Vedbaek, Denmark) according to the manufacturer’s
protocol. The Hy3™ -labeled samples were mixed pairwise with a
Hy5™ -labeled reference probe and hybridized to the miRCURY
LNA™ miRNA Array 7th Gen (Exiqon A/S, Vedbaek, Denmark)
which contains capture probes targeting all miRNAs registered
in the miRBase 18.0 (human, mouse, or rat)1 as well as viral
miRNAs related to these species. Hybridization was performed
according to the miRCURY LNA™ miRNA Array Instruction
manual (Exiqon A/S, Vedbaek, Denmark) using a Tecan HS4800™
hybridization station (Tecan Austria GmbH, Salzburg, Austria).
1www.mirbase.org
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After hybridization, microarray slides were scanned and stored
in an ozone free environment (ozone below 2.0 ppb) in order
to prevent potential bleaching of fluorescent labels. The miR-
CURY LNA™ miRNA Array slides were scanned using the Agilent
G2565BA Microarray Scanner System (Agilent Technologies, Inc.,
USA). Image analysis was carried out with ImaGene® 9 miRCURY
LNA™ miRNA Array Analysis Software (Exiqon A/S, Vedbaek,
Denmark).
MICROARRAY DATA PROCESSING
Pre-processed microarray data was provided by Exiqon (Exiqon
A/S, Vedbaek, Denmark). Accordingly, the description of microar-
ray data processing is based on information provided by Exiqon:
Signal intensity was the basis of data filtering. Background cor-
rection of quantified signals was performed via subtraction of the
median global background from the median local background
from the intensity of signals (Normexp with offset value 10) and
resulted in the exclusion of two samples of the experimental group
“no-shock-fluoxetine” (Figures 3B and 4). Normalization of data
was performed with the global Lowess (locally weighted scatter-
plot smoothing) regression algorithm (37). All calculations have
been performed using the software R/bioconductor employing
mainly the limma package. Comparisons of miRNA expression
values between experimental groups were performed using mod-
erated t -statistics with standard errors moderated across genes, i.e.,
shrunk toward a common value, using a simple Bayesian model.
This has the effect of borrowing information from the ensemble
of genes to aid with inference about each individual gene (38).
P-values were corrected for multiple testing by the Benjamini
and Hochberg adjustment method to control for false positive
results.
With the corrected p-values delivered by Exiqon (Exiqon A/S,
Vedbaek, Denmark), we performed unsupervised hierarchical
clustering analyses (HCA) in which we included the top 50 miRNA
candidates with the lowest corrected p-values. HCA results are
depicted in heatmaps which we generated by a web-based tool
provided by the Los Alamos National Laboratory HIV sequence
database2. For HCA, the complete-linkage method together with
the Euclidean distance measure was employed. Complete-linkage
clustering (by Euclidean distance) between sample subsets is
represented by dendrograms (Figures 2–4).
2http://www.hiv.lanl.gov/content/sequence/HEATMAP/heatmap.html
REVERSE TRANSCRIPTASE QUANTITATIVE PCR
For reverse transcriptase quantitative polymerase chain reaction
(RT-qPCR), which was performed at the MPI-P, we employed
either pre-designed LNA™ PCR primer sets for miRCURY LNA™
Universal RT microRNA PCR or Custom LNA™ PCR primers
(UniRT) (Exiqon A/S, Vedbaek, Denmark). A list of all primer sets
and their respective target sequences used is provided in Table 1.
We used the miRCURY LNA™ miRNA PCR system first strand
synthesis kit for poly-adenylation (poly-A-tailing) and reverse
transcription (input of total RNA: 100 ng) according to the manu-
facturer’s protocol (Exiqon A/S,Vedbaek, Denmark). Then, 1µl of
1:80 diluted cDNA was amplified by RT-qPCR in 5µl SYBR Green
PCR master mix containing 0.25 mM of LNA™ miRNA specific
primer sets (Table 1). The total reaction volume was 10µl. RT-
qPCR was performed on the LightCycler® 480 instrument (Roche
Diagnostics, Penzberg, Germany). Each sample was analyzed in
duplicate in every run, i.e., for each miRNA candidate tested.
Cycling conditions were as follows: denaturation step 95°C 5 min
followed by 45 loops of a two-segment amplification step (95°C,
30 s, 62°C, 1 min). A standard curve was generated for each indi-
vidual plate assay with 1:10, 1:100, and 1:1000 dilutions and PCR
efficiencies were calculated. Cp values were obtained with the soft-
ware provided by the manufacturer (Roche Diagnostics, Penzberg,
Germany). MiRNA entities for normalization were selected via
NormFinder analysis based on microarray data (39) and mmu-
miR-100-5p was used for normalization. Relative expression was
calculated by the ∆∆C t method (40).
miRNA TARGET PREDICTION AND GENE ONTOLOGY ANALYSIS
Materials and methods for miRNA target prediction and gene
ontology (GO) analysis are described in detail in the Section
“Results.”
RESULTS
FLUOXETINE COUNTERACTS THE LONG-LASTING PTSD-LIKE
SYNDROME IN MICE
To analyze the impact of traumatic stress on miRNA profiles in
mouse PFC, we employed a well-established mouse model for
PTSD that we (28, 29, 41–43) and also other research groups
used, at least in slightly modified ways (44–46), for previous
experiments. The electric footshock-elicited murine PTSD-like
syndrome can be effectively counteracted by the orally adminis-
tered SSRI antidepressant fluoxetine (28, 29) and, as we published
Table 1 | List of primer sets used for RT-qPCR.
Target name Product no./design ID (custom) Target miRNA sequence
mmu-miR-33-5p 204632 GUGCAUUGUAGUUGCAUUGCA
mmu-miR-100-5p 204133 AACCCGUAGAUCCGAACUUGUG
mmu-miR-1971 206999 (custom)/design ID 212160 GUAAAGGCUGGGCUGAGA
mmu-miR-1947-3p 206999 (custom)/design ID 212154 GCACUGAGCUAGCUCUCCCUCC
rno-miR-3559-3p 206999 (custom)/design ID 212147 AUGUAGUACUGAGUCUGUCGUG
ebv-miR-BART8-3p 206999 (custom)/design ID 212150 GUCACAAUCUAUGGGGUCGUAGA
We employed either pre-designed LNA™ PCR primer sets for miRCURY LNA™ Universal RT microRNA PCR or Custom LNA™ PCR primers (UniRT) (Exiqon A/S,
Vedbaek, Denmark). The primer sets are designed for detection of the respective target sequences.
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FIGURE 1 | Fluoxetine counteracts the long-lasting PTSD-like
syndrome in mice. Male C57BL/6NCrl mice (n= 6 per group) were either
subjected to a single electric footshock (“shock”) or, mock treatment
(“no-shock”). Subsequently, both shocked and non-shocked mice were
treated with either fluoxetine (20 mg/kg/day) (“fluoxetine”) or, for control,
with drinking water (“vehicle”) for 28 days (A). On day 28 after footshock
or mock-treatment their freezing response to a neutral tone was assessed
in a neutral experimental context (generalized fear response) (B). On
day 29, the dose of fluoxetine was halved (i.e., 10 mg/kg/day) prior to
treatment discontinuation on day 31. On days 59–61, PTSD-like behavior
was analyzed: first, we assessed the intensity of the acoustic startle reflex
(ASR) in response to white noise pulses of 50 dB (background, BG)
and 75, 90, 105, and 115 dB (C). Then, we evaluated the generalized fear
response by assessment of the freezing response both in a neutral
experimental context (D) and in a grid context similar to the shock
chamber (E). Finally, the conditioned fear response was analyzed by
evaluation of the freezing response in the shock context (re-exposure to
shock chamber) (F). Freezing duration was assessed for a total of 3 min.
The absolute time of immobility except respiratory movements was
normalized to this 3 min observation interval (Freezing [%]). Presented
data are means±SEM. Statistical analysis was performed using two-way
ANOVA and Bonferroni post hoc tests. Statistical significance of
Bonferroni post hoc tests is indicated, for comparison of the groups
“no-shock-vehicle” versus “shock-vehicle” by *p<0.05, **p<0.01,
***p<0.001; respectively; comparison of groups “shock-vehicle” versus
“shock-fluoxetine” by ##p<0.01. See Section “Results” for statistical data.
recently, lasts at least until day 60 after shock application (28).
First, we had to re-establish the behavioral syndrome-inducing
effect of footshock and the relieving action of fluoxetine in the
mouse cohort studied here: in contrast to our expectations (28,
29), and despite a significant effect of shock (F 1,20 shock= 5.696,
p= 0.027), the relative increase of the generalized fear response of
shocked mice in the neutral context was not statistically significant
after Bonferroni correction on day 60 (Figure 1D) but at least
on day 28 (Figure 1B, t = 6.461, p< 0.001). The results of the
other behavioral experiments turned out as expected: on day 59/60
after their subjection to shock, in comparison to mock-treated
control mice, shocked mice exhibited a significantly stronger gen-
eralized fear response (in a context similar to the shock cham-
ber) (Figure 1E, t = 4.058, p< 0.01) as well as more pronounced
acoustic startle (Figure 1C, t = 4.468, p< 0.001) and conditioned
fear responses (Figure 1F, t = 3.609, p< 0.01). Moreover, fluox-
etine treatment drastically reduced trauma-mediated behavioral
changes (Figure 1B: t = 5.630, p< 0.001, Figure 1C: t = 3.939,
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p< 0.01, Figure 1E: t = 4.193, p< 0.001, Figure 1F: t = 3.505,
p< 0.01).
The behavioral consequences of stress exposure make this
mouse model an animal model of PTSD, not the type or intensity
of the stressor applied. The relatively increased conditioned and
generalized fear responses in footshocked mice mirror the PTSD-
associated avoidance behavior in humans: In most PTSD patients,
the aversive avoidance of trauma-related reminders generalizes
over time in sense that someday also trauma-unrelated cues suf-
fice to elicit an intense avoidance anxiety. Moreover, the relatively
increased startle response in footshocked mice has been repeat-
edly described also in PTSD patients (47–49). Hence, it reflects
trauma-elicited nervous hyperexcitability in both men and mice.
Other PTSD animal models employ more intense stressors in order
to better model their traumatizing nature (50, 51).
TRAUMATIC FOOTSHOCK PER SE DOES NOT SIGNIFICANTLY ALTER
MOUSE PFC miRNA PROFILES IN THE LONG-TERM
To avoid molecular analyses to be influenced by acute effects of the
behavioral testing procedure, we harvested mouse brains 2 weeks
after behavioral analyses. For preparation of total RNA and subse-
quent miRNA profile analyses, PFCs were dissected from six mice
per group. With the aim to identify miRNA candidates regulated
by traumatic stress and/or by fluoxetine treatment, we subjected
all of these 24 PFC total RNA samples to miRNA microarray
analysis. After background correction and normalization, expres-
sion values were subjected to pairwise t -testing (no-shock-vehicle
versus shock-vehicle; shock-vehicle versus shock-fluoxetine; no-
shock-fluoxetine versus shock-fluoxetine; no-shock-vehicle versus
no-shock-fluoxetine) and the resulting p-values were Benjamini–
Hochberg corrected. Then, miRNAs were ranked by corrected
p-values and the resulting top 50 candidates, i.e., the miRNAs
with the lowest p-values, were subjected to unsupervised HCA.
We performed four HCAs in total (Figures 2–4).
First, we looked for miRNAs regulated by traumatic footshock:
unsupervised HCA of footshocked versus non-shocked groups
(both vehicle-treated) revealed that samples clustered, with one
exception, according to treatment by their miRNA expression val-
ues (Figure 2). However, pairwise comparison of miRNA expres-
sion profiles showed that no miRNA was significantly differentially
expressed between these two groups. Thus, traumatic footshock
causes a long-lasting PTSD-like syndrome in mice (Figure 1) but
does not significantly alter long-term miRNA expression in mouse
PFC (Figure 2).
FLUOXETINE TREATMENT SIGNIFICANTLY ALTERS THE EXPRESSION OF
SEVERAL miRNAs IN THE PFC OF SHOCKED MICE
Then, we looked for the influence of fluoxetine treatment
on miRNA profiles of shocked mice: unsupervised HCA of
shocked fluoxetine-treated (shock-fluoxetine) versus shocked
vehicle-treated (shock-vehicle) groups revealed that samples clus-
tered perfectly according to treatment (Figure 3A). Moreover,
comparison of these two groups, i.e., the shock-vehicle versus
the shock-fluoxetine group, revealed, that therapeutic (Figure 1)
fluoxetine treatment significantly reduced the relative expression
of two miRNA candidates analyzed, namely of rno-miR-3559-
3p [fold change (FC) 0.29, corrected p (corr. p)< 0.003] and of
mmu-miR-1971 (FC 0.82, corr. p< 0.05) (Figure 3A, highlighted
in bright pink) and furthermore decreased the expression of two
other miRNAs [at least on the level of a trend toward statisti-
cal significance (i.e., with p< 0.1)], namely the expression levels
of ebv-miR-BART8-3p (FC 0.53, corr. p< 0.06) and of mmu-
miR-1947-3p (FC 0.67, corr. p< 0.06) (Figure 3A, highlighted
in bright blue).
Next, to further dissect the individual contributions of trau-
matic stress and fluoxetine treatment on mouse PFC miRNA
signatures, we compared the shock-fluoxetine group to the no-
shock-fluoxetine group (Figure 3B) and to the no-shock-vehicle
group (Figure 4). Two samples of the no-shock-fluoxetine group
had to be excluded from microarray analysis during array data
processing. HCA of the no-shock-fluoxetine group versus the
shock-fluoxetine group showed that the two groups did not cluster
correctly according to treatment. However, pairwise compari-
son of these two groups revealed that, the relative expression of
mmu-miR-33-5p was enhanced, at least with a statistical trend
(FC 1.26, corr. p< 0.07) and the relative expression of rno-miR-
3559-3p was decreased, also with a statistical trend (FC 0.80,
corr. p< 0.07) in PFC of shock-fluoxetine mice (Figure 3B,
both highlighted in bright blue). Although the HCA of the
no-shock-fluoxetine group versus the no-shock-vehicle group
illustrates that, with one exception, the respective samples clus-
tered according to treatment, pairwise comparisons of these two
groups revealed no significant differences in miRNA profiles
(Figure 4). Notably, mmu-miR-3559-3p emerged as a regulated
miRNA candidate in two different pairwise comparisons since its
expression was altered in shock-fluoxetine mice in comparison
to both shock-vehicle (Figure 3A) and no-shock-fluoxetine mice
(Figure 3B).
Taken together, microarray analyses revealed that, in shocked
mice, on day 74 after subjection of mice to footshock, the thera-
peutic effect of fluoxetine (Figure 1) went along with a significant
decrease in prefrontal cortical rno-miR-3559-3p and mmu-miR-
1971 expression as well as with a trend of reduction in prefrontal
cortical ebv-miR-BART8-3p and mmu-miR-1947-3p expression
(Figure 3A). Finally, our analyses revealed that none of the miRNA
candidates tested was altered by traumatic stress per se (Figure 2)
or by fluoxetine treatment per se (Figure 4) which suggests that
fluoxetine treatment interacts with traumatic stress to alter the
expression levels of the mentioned miRNA candidates.
RT-qPCR ANALYSIS CONFIRMED THAT FLUOXETINE TREATMENT
ALTERS THE EXPRESSION OF mmu-miR-1971 AND mmu-miR-33-5p IN
THE PFC OF SHOCKED MICE
Two out of the five array-identified miRNA candidates (rno-miR-
3559-p, mmu-miR-1971, ebv-miR-BART8-3p, mmu-miR-1947-
3p, mmu-miR-33-5p) could be validated by miRCURY LNA™
RT-qPCR: calculation of the statistical significance of RT-qPCR
results with two-way ANOVA followed by Bonferroni post hoc cor-
rection confirmed a statistical trend toward a fluoxetine-mediated
increase in prefrontal cortical mmu-miR-33-5p expression in
shock-fluoxetine mice comparison to no-shock-fluoxetine mice
(Figure 5C: Bonferroni posttest of shock-fluoxetine versus
no-shock-fluoxetine: t = 2.205, p= 0.055). Most important, we
observed a statistically significant reduction in mmu-miR-1971
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FIGURE 2 |Traumatic footshock does not significantly alter mouse
PFC miRNA profiles in the long-term. Here, results of the hierarchical
cluster analysis (HCA) of the footshocked vehicle-treated (shock-vehicle)
versus the non-shocked vehicle-treated (no-shock-vehicle) samples are
presented in a heatmap. The top 50 miRNA candidates with the lowest
corrected p-values (resulting from pairwise comparison of the two groups
shown here) were included. MiRNA expression levels were determined
with LNA™ miRNA microarray analysis of mouse prefrontal cortex (PFC)
total RNA samples. Samples were collected on day 74 after footshock
(“shock”) or mock treatment (“no-shock”) from male C57/BL6/N mice
(n=6 per group). Each row represents a miRNA and each column
represents a sample. Dendrograms represent complete-linkage clustering
(by Euclidean distance) between samples. The sample clustering tree is
shown on the top. The color scale illustrates the intensities of the relative
miRNA expression levels: decreased scores are represented in red and
increased in green, with intensity encoding magnitude. See Section
“Materials and Methods” for statistical procedures. Vehicle, drinking water
(solvent of fluoxetine).
expression in the PFC of shock-fluoxetine mice in comparison
to shock-vehicle mice (Figure 5A: Bonferroni posttest of shock-
vehicle versus shock-fluoxetine: t = 2.509, p< 0.050). RT-qPCR
data do not allow the conclusion that fluoxetine rescues the
footshock-induced increase in mmu-miR-1971 expression, since
the latter failed to survive statistical correction (Figure 5A).
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FIGURE 3 | Microarray analysis revealed fluoxetine treatment to
significantly alter the expression of several miRNAs in the PFC of
shocked mice. Here, results of the hierarchical cluster analysis (HCA) of
(A) the footshocked vehicle-treated (shock-vehicle) versus the footshocked
fluoxetine-treated (shock-fluoxetine) groups and of (B) the non-shocked
fluoxetine-treated (no-shock-fluoxetine) versus the footshocked
fluoxetine-treated (shock-fluoxetine) groups are presented in heatmaps.
The top 50 miRNA candidates with the lowest corrected p-values
[resulting from pairwise comparison of groups shown in (A,B),
respectively] were included. MiRNA expression levels were determined
with LNA™ miRNA microarray analysis of mouse prefrontal cortex (PFC)
samples. Samples were collected on day 74 after footshock (“shock”) or
mock treatment (“no-shock”) of male C57/BL6/N mice. Each row
represents a miRNA and each column represents a sample. Dendrograms
represent complete-linkage clustering (by Euclidean distance) between
samples. The sample clustering tree is shown on the top. The color scale
illustrates the intensities of the relative miRNA expression levels:
decreased scores are represented in red and increased in green, with
intensity encoding magnitude. Significant alterations in miRNA expression
levels determined by pairwise t -tests are highlighted in bright pink (corr.
p<0.05), statistical trends (corr. p< 0.1) in bright blue. Note that two
samples of the no-shock-fluoxetine group were excluded during data
processing (shock-vehicle: n=6 per group; shock-fluoxetine: n=6;
no-shock-fluoxetine: n=4). Statistical procedures are explained in the
Section “Materials and Methods” and data are presented in the Section
“Results” Vehicle, drinking water (solvent of fluoxetine).
Furthermore, despite a significant treatment effect in the two-way
ANOVA (F 1,20 shock= 4.494, p= 0.030), Bonferroni posttests did
not detect any significant fluoxetine-mediated changes in relative
expression of mmu-miR-1947-3p. Thus, we cannot consider
mmu-miR-1947-3p as a fully validated candidate (Figure 5B).
Finally, despite repetitive tries and employment of optimized
LNA™ -technology based miRNA primer sets, expression of
rno-miR-3559-3p and ebv-miR-BART8-3p could not be detected
by RT-qPCR. Given that, we speculate that the array-detected
rno-miR-3559-3p and ebv-miR-BART8-3p signals might possibly
represent technical artifacts.
In summary, the most important conclusion of this study is that
in the PTSD mouse model studied here, the therapeutic action of
fluoxetine (Figure 1) is accompanied by a significant reduction
in prefrontal cortical mmu-miR-1971 expression on day 74 after
shock exposure (Figures 3A and 5B).
miRNA TARGET PREDICTION AND GENE ONTOLOGY ANALYSIS
Finally, to get an idea of the potential role of mmu-miR-1971
and mmu-miR-33-5p in PTSD and of their general function,
we performed an in silico analysis of target genes regulated
by these two miRNA candidates: analysis performed with the
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FIGURE 4 | In non-shocked mice, fluoxetine treatment does not
significantly alter mouse PFC miRNA profiles in the long-term. Here,
results of the hierarchical cluster analysis (HCA) of the non-shocked
vehicle-treated (no-shock-vehicle) versus the non-shocked fluoxetine-treated
(no-shock-fluoxetine) groups are presented in a heatmap. The top 50 miRNA
candidates with the lowest corrected p-values (resulting from pairwise
comparison of the two groups shown here) were included. MiRNA
expression levels were determined with LNA™ miRNA microarray analysis of
mouse prefrontal cortex (PFC) total RNA samples. Samples were collected on
day 74 after footshock (“shock”) or mock treatment (“no-shock”) of male
C57/BL6/N mice (no-shock-vehicle: n=6 per group: no-shock-fluoxetine:
n=4). Each row represents a miRNA and each column represents a sample.
Dendrograms represent complete-linkage clustering (by Euclidean distance)
between samples. The sample clustering tree is shown on the top. The color
scale illustrates the intensities of the relative miRNA expression levels:
decreased scores are represented in red and increased in green, with
intensity encoding magnitude. See Section “Materials and Methods” for
statistical procedures. Vehicle, drinking water (solvent of fluoxetine).
miRWalk database3 (52) revealed several validated target genes of
mmu-miR-33-5p (Table 3), but none of mmu-miR-1971. Then,
we used computational methods to predict potential target genes
3http://www.umm.uni-heidelberg.de/apps/zmf/mirwalk/mirnatargetpub.html
of mmu-miR-1971: we applied TargetScanMouse 6.24 (53) and
MirTarget25 (54, 55); we included only those predicted target genes
4http://www.targetscan.org/mmu_61/
5http://mirdb.org/miRDB/
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FIGURE 5 | RT-qPCR analysis confirmed that fluoxetine treatment
alters the expression of mmu-miR-1971 and mmu-miR-33-5 in the PFC
of shocked mice. Depicted are results of the RT-qPCR analysis of the
relative expression levels of the candidate microRNAs mmu-miR-1971 (A),
mmu-miR-1947-3p (B), and mmu-miR-33-5p (C) compared between the
no-shock-vehicle, no-shock-fluoxetine, shock-vehicle, and shock-fluoxetine
groups (n=6 per group). Prefrontal cortex (PFC) samples employed for
RT-qPCR analyses were identical to those used for microarray analyses.
Mmu-miR-100-5p was used for normalization using the ∆∆C t method.
Presented data are means±SEM. Statistical analysis was performed using
two-way ANOVA and Bonferroni post hoc tests. Statistical significance of
Bonferroni post hoc tests is indicated by *p<0.05. See Section “Results”
for statistical data. Vehicle, drinking water (solvent of fluoxetine).
that were identified with both approaches into subsequent GO
analysis by employing GenericGeneOntologyTermFinder6 (56)
and REViGO7 (57) (Table 2). The molecular functions of pre-
dicted mmu-miR-1971 target genes are mainly associated with
small molecule and nucleic acid binding (Table 2). Moreover,
most of them are involved in metabolic processes such as organic
compound and RNA metabolism (Table 2).
6http://go.princeton.edu/cgi-bin/GOTermFinder
7http://revigo.irb.hr/
Table 2 | Gene ontology analysis of predicted mmu-miR-1971 target
genes.
GO ID GO term Corr. p-value
GO MOLECULAR FUNCTION
GO:0005488 Binding 8.98E−09
GO:0097159 Organic cyclic compound binding 2.97E−10
GO:0003723 RNA binding 6.98E−04
GO:0003676 Nucleic acid binding 2.54E−10
GO:0000166 Nucleotide binding 2.63E−04
GO:0036094 Small molecule binding 7.58E−04
GO:0043167 Ion binding 3.22E−05
GO:0005515 Protein binding 7.20E−05
GO:0003677 DNA binding 3.85E−05
GO BIOLOGICAL PROCESS
GO:0006725 Cellular aromatic compound metabolic
process
2.71E−06
GO:0008152 Metabolic process 2.50E−05
GO:0009987 Cellular process 1.02E−06
GO:0065007 Biological regulation 2.47E−06
GO:0006606 Protein import into nucleus 6.,19E−03
GO:0034654 Nucleobase-containing compound
biosynthetic process
1.02E−05
GO:0046483 Heterocycle metabolic process 2.27E−06
GO:0044238 Primary metabolic process 6.15E−06
GO:0019438 Aromatic compound biosynthetic
process
1.55E−05
GO:0071704 Organic substance metabolic process 3.73E−05
GO:0016071 mRNA metabolic process 7.31E−04
GO:0018130 Heterocycle biosynthetic process 1.65E−05
GO:0009058 Biosynthetic process 9.77E−05
GO:0000398 Nuclear mRNA splicing, via
spliceosome
7.18E−04
GO:0044271 Cellular nitrogen compound
biosynthetic process
2.77E−05
GO:0006807 Nitrogen compound metabolic process 8.77E−06
GO:0010468 Regulation of gene expression 4.09E−08
GO:0050794 Regulation of cellular process 1.33E−04
GO:0043170 Macromolecule metabolic process 1.36E−05
GO:0010467 Gene expression 5.25E−08
GO:0019222 Regulation of metabolic process 1.60E−04
GO:0044237 Cellular metabolic process 8.81E−06
GO:0016070 RNA metabolic process 8.04E−08
GO:0044260 Cellular macromolecule metabolic
process
4.73E−06
Indicated are gene ontology IDs (GO ID), gene ontology terms (GO term), and
corrected p-values as determined by GenericGeneOntologyTermFinder (http:
// go.princeton.edu/ cgi-bin/ GOTermFinder ) and REViGO (http:// revigo.irb.hr/ ).
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Table 3 | Gene ontology analysis of validated mmu-miR-33-5p target genes.
GO ID GO term Annotated genes Corr. p-value
GO MOLECULAR FUNCTION
GO:0005488 Binding Zp3, Lin28, Hprt1, Mos, H2afx, Ctdspl, H2afz, Fas, Rfpl4, Mt1, Ccnb2, Mbp,
Dppa3, H1foo, Cd320, Dicer1, Hnt, Cpeb1, Srebf2, Ldlr, Cpt1a, Bmp4, Camk2g,
Fgf21, Ccne1, Dnmt3b, Sycp3, Sirt6, Pou5f1, Abcg1
1.02E−06
GO:0035198 miRNA binding Dicer1, Lin28, Pou5f1 8.49E−06
GO:0097159 Organic cyclic compound
binding
H1foo, Cd320, Dicer1, Cpeb1, Srebf2, Lin28, Hprt1, Camk2g, Mos, H2afx, H2afz,
Dnmt3b, Sycp3, Sirt6, Pou5f1, Abcg1
5.09E−03
GO:0005515 Protein binding Zp3, Lin28, Hprt1, H2afx, H2afz, Fas, Rfpl4, Ccnb2, Mbp, Dppa3, Cd320, Dicer1,
Cpeb1, Srebf2, Ldlr, Cpt1a, Bmp4, Camk2g, Fgf21, Ccne1, Dnmt3b, Sycp3, Abcg1,
Pou5f1
1.02E−06
GO BIOLOGICAL PROCESS
GO:0000003 Reproduction H1foo, Dicer1, Zp3, Cpeb1, Lin28, Bmp4, Mos, H2afx, Ifitm3, Sycp3 5.11E−04
GO:0048610 Cellular process involved in
reproduction
H1foo, Zp3, Cpeb1, Lin28, Sycp3, Bmp4, Mos, H2afx 4.52E−05
GO:0032502 Developmental process Zp3, Lin28, Hprt1, H2afz, Fas, Ccnb2, Mbp, Dppa3, Hnt, Dicer1, Bmp4, Camk2g,
Ccne1, Dnmt3b, Sycp3, Abcg1, Pou5f1
3.72E−03
GO:0042221 Response to chemical
stimulus
Mbp, Dicer1, Srebf2, Lin28, Hprt1, Bmp4, Fgf21, Ifitm3, Fas, Dnmt3b, Mt1, Abcg1,
Pou5f1
2.83E−03
GO:0071840 Cellular component
organization or biogenesis
Hprt1, H2afx, H2afz, Fas, Ccnb2, Mbp, H1foo, Dppa3, Hnt, Dicer1, Cpeb1, Cpt1a,
Bmp4, Dnmt3b, Sycp3, Abcg1, Pou5f1, Sirt6
1.33E−04
GO:0003133 Endodermal-mesodermal
cell signaling
Bmp4, Pou5f1 3.54E−03
GO:0006325 Chromatin organization Dppa3, H1foo, H2afx, H2afz, Sycp3, Dnmt3b, Pou5f1, Sirt6 1.36E−04
GO:0006259 DNA metabolic process Dppa3, H1foo, Bmp4, H2afx, Ccne1, H2afz, Sycp3, Dnmt3b, Sirt6 2.32E−04
GO:0022402 Cell cycle process H1foo, Dicer1, Cpeb1, Camk2g, Bmp4, Mos, H2afx, Sycp3, Ccnb2 5.36E−04
GO:0045595 Regulation of cell
differentiation
Mbp, Dicer1, Hnt, Lin28, Bmp4, Ccne1, Fas, Dnmt3b, Pou5f1, Abcg1 6.50E−04
GO:0007049 Cell cycle H1foo, Dicer1, Cpeb1, Camk2g, Bmp4, Mos, H2afx, Ccne1, Sycp3, Ccnb2 1.05E−03
GO:0006807 Nitrogen compound
metabolic process
Zp3, Lin28, Hprt1, H2afx, H2afz, H1foo, Dppa3, Dicer1, Srebf2, Cpeb1, Cpt1a, Ldlr,
Bmp4, Ccne1, Dnmt3b, Sycp3, Abcg1, Pou5f1, Sirt6
1.44E−03
GO:0040029 Regulation of gene
expression, epigenetic
Dppa3, Dicer1, Dnmt3b, Lin28, Pou5f1 1.29E−03
GO:0048519 Negative regulation of
biological process
Mbp, Dppa3, Dicer1, Zp3, Hnt, Srebf2, Lin28, Bmp4, Ifitm3, Fas, Dnmt3b, Mt1,
Sycp3, Pou5f1, Abcg1
1.78E−03
GO:0045834 Positive regulation of lipid
metabolic process
Zp3, Ldlr, Cpt1a, Abcg1 7.65E−03
GO:0016458 Gene silencing Dicer1, Dnmt3b, Lin28, Pou5f1 7.65E−03
GO:0010033 Response to organic
substance
Dicer1, Srebf2, Lin28, Hprt1, Bmp4, Fgf21, Ifitm3, Fas, Dnmt3b, Abcg1, Pou5f1 4.09E−03
GO:0050794 Regulation of cellular
process
Zp3, Lin28, Hprt1, Mos, Ifitm3, Fas, Mt1, Ccnb2, Mbp, Dppa3, Hnt, Dicer1, Cpeb1,
Srebf2, Ldlr, Cpt1a, Bmp4, Fgf21, Ccne1, Dnmt3b, Sycp3, Sirt6, Abcg1, Pou5f1
4.26E−03
(Continued)
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Table 3 | Continued
GO ID GO term Annotated genes Corr. p-value
GO:0071824 Protein-DNA complex
subunit organization
H1foo, H2afz, Sycp3, H2afx 5.38E−03
GO:0080090 Regulation of primary
metabolic process
Dppa3, Dicer1, Zp3, Cpeb1, Srebf2, Ldlr, Cpt1a, Lin28, Hprt1, Bmp4, Ccne1,
Dnmt3b, Sirt6, Pou5f1, Ccnb2, Abcg1
7.43E−03
GO:0006323 DNA packaging H1foo, H2afz, Sycp3, H2afx 7.37E−03
GO:0003130 BMP signaling pathway
involved in heart induction
Bmp4, Pou5f1 3.54E−03
GO:0034641 Cellular nitrogen
compound metabolic
process
Zp3, Lin28, Hprt1, H2afx, H2afz, H1foo, Dppa3, Dicer1, Srebf2, Cpeb1, Cpt1a, Ldlr,
Bmp4, Ccne1, Dnmt3b, Sycp3, Abcg1, Pou5f1, Sirt6
5.92E−04
GO:0050793 Regulation of
developmental process
Mbp, Dicer1, Zp3, Hnt, Lin28, Bmp4, Ccne1, Fas, Dnmt3b, Pou5f1, Abcg1 1.71E−03
GO:0048523 Negative regulation of
cellular process
Mbp, Dppa3, Dicer1, Zp3, Hnt, Srebf2, Lin28, Bmp4, Ifitm3, Fas, Dnmt3b, Mt1,
Sycp3, Pou5f1, Abcg1
4.54E−04
Indicated are gene ontology IDs (GO ID), gene ontology terms (GO term), the annotated gene names, and corrected p-values as determined by GenericGeneOntol-
ogyTermFinder (http:// go.princeton.edu/ cgi-bin/ GOTermFinder ) and REViGO (http:// revigo.irb.hr/ ).
Then, to characterize possible molecular functions of vali-
dated mmu-miR-33-5p regulated targets, we performed GO analy-
sis as described above. We found that most of the validated
mmu-miR-33-5p targets are associated with protein, miRNA,
and organic compound binding (Table 3). Furthermore, many
of the validated mmu-miR-33-5p target genes are involved in
cellular and developmental processes, and most important, in epi-
genetic regulation of gene expression and lipid metabolic processes
(Table 3).
Taken together, target prediction and GO analyses revealed sev-
eral predicted target genes of mmu-miR-1971 and several validated
target genes mmu-miR-33-5p which might possibly be involved
inter alia in PTSD pathobiology or fluoxetine-mediated alter-
ations of molecular pathways. Interestingly, amongst these target
genes we found none which had previously been repetitively asso-
ciated with PTSD, like for instance FKBP5 (8), CDK5 (58), or
synapsin (28).
DISCUSSION
Here, we present the first study exploring miRNA expression pro-
files in a PTSD mouse model. In summary, we demonstrate that
the therapeutic action of fluoxetine in shocked mice (Figure 1)
is correlated with a significant reduction in prefrontal cortical
mmu-miR-1971 expression levels on day 74 after shock expo-
sure (Figures 1 and 5A). The significance of this finding is
supported by results of the unsupervised HCA of the shock-
vehicle versus the shock-fluoxetine group which revealed that
samples of both groups clustered perfectly according to treatment
(Figure 3A) thereby demonstrating that the miRNome is a factor
that contributes to biological differences in these two groups. RT-
qPCR data do not allow the conclusion that fluoxetine rescues
the footshock-induced increase in mmu-miR-1971 expression,
since the latter failed to survive correction for multiple testing
(Figure 5A). Furthermore, our analyses revealed a trend toward
an increase of prefrontal cortical mmu-miR-33-5p expression in
shock-fluoxetine mice in comparison to no-shock-fluoxetine mice
(Figure 5C). Interestingly, we found that traumatic stress per se
and fluoxetine treatment per se did not lead to significant alter-
ations of mouse miRNA profiles on day 74 after trauma exposure
(Figures 2 and 4) which suggests that fluoxetine interacts with
traumatic stress to alter expression levels of mmu-miR-1971 and
mmu-miR-33-5p (Figures 5A,C). To the best of our knowledge,
these two miRNA candidates have not been associated with psy-
chiatric disorders so far. MiR-1971 has hitherto not even been
associated with the central nervous system (CNS). Instead, in the
only study reporting expression level changes of miR-1971 demon-
strated that, in the bone marrow, miR-1971 was differentially
expressed between patients suffering from acute lymphoblastic
leukemia (ALL) and healthy donors (59). However, to our knowl-
edge, the in that study newly identified miRNA sequence, which
was termed hsa-miR-1971 thereby representing it as the human
homolog of murine mmu-miR-1971, is not annotated in miRBase
19.0. Our miRNA target prediction and GO analysis revealed that
for miR-1971 no target genes have been validated so far (Table 2).
Hence, regulation and function of miR-1971 are largely unex-
plored yet and await further studies. However, GO analysis of
predicted miR-1971 target genes allude that this above-average
small (18nt) miRNA candidate might be involved inter alia in basic
metabolic processes like heterocycle and organic substance metab-
olism (Table 2: p= 2.27E−06 and p= 3.73E−05, respectively);
neurotransmitters like serotonin or modulators of the serotoner-
gic tone might belong to the organic substances whose metabolism
is targeted by miR-1971, but, however, our GO analysis provided
no direct hint for this speculation.
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In contrast, miR-33 has been studied more intensely. A fun-
damental biological role of miR-33-5p (previous miRBase ID:
miR-33) is suggested by the fact that, according to miRBase 18.0,
its sequence is highly conserved in human, mouse, and rat. MiR-
33 was found to be downregulated in the hippocampus of rats
with status epilepticus (60), to regulate the cell cycle (61, 62),
to be associated with mouse atherosclerosis (63, 64), as well as
with metabolism of cholesterol (65, 66). The latter finding is sup-
ported by our GO analysis which revealed the biological process
termed “positive regulation of lipid metabolic processes” to be
significantly enriched among validated mmu-miR-33-5p target
genes (Table 3: p= 7.65E−03). Low blood levels of cholesterol
were found to be associated with suicidality (67, 68), while PTSD
patients were repeatedly reported to exhibit elevated cholesterol
blood levels (69, 70). Cholesterol biosynthesis in glial cells was
shown to be influenced by fluoxetine and other antidepressants
(59). In turn, most interestingly, there is strong evidence for an
influence of the cholesterol metabolism on fluoxetine treatment
response both in rodents (60) and in humans (61). The synopsis of
these findings fuels the speculation that in the PTSD mouse model
studied here, the shock× fluoxetine interaction-mediated increase
of prefrontal cortical mmu-miR-33-5p expression (Figures 3B
and 5C) might contribute to the previously reported influence
of cholesterol metabolism on the response to fluoxetine treatment
(59, 60). This synoptic speculation is worth addressing in future
studies. However, even though our analyses do support an involve-
ment of mmu-miR-33-5p in fluoxetine-mediated processes, they
do neither speak for nor against the involvement of mmu-miR-
33-5p in the therapeutic action of fluoxetine since we did not find
significant mmu-miR-33-5p expression level differences between
vehicle-treated and fluoxetine-treated shocked mice. Instead, our
data suggest an involvement of mmu-miR-1971 in the therapeutic
action of fluoxetine in footshocked mice.
Interestingly, fluoxetine was shown previously to regulate
miRNA expression, namely to alter the expression of miR-16 in
serotonergic raphe nuclei (71). However, in the here presented
study which analyzed miRNA expression levels in another brain
region, i.e., the PFC, in a different experimental context, miR-
16 expression was not significantly altered by fluoxetine treat-
ment. Since changes in miRNA expression can occur rapidly (72),
we suppose that both traumatic stress and fluoxetine treatment
might exert even stronger effects on miRNA expression at earlier
time-points after challenge. At the late posttrauma time-point
tested here, the consequences of trauma-stress and fluoxetine-
mediated alterations of miRNA expression probably dominate
alterations in miRNA expression itself. Moreover, it would also
be interesting to evaluate miRNA profiles in other brain regions
associated with PTSD, like for instance the hippocampus and the
amygdala (31). To check for the generalizability of the results pre-
sented here, our findings should be validated in another mouse
cohort and in other animal models for PTSD. Most important,
it also remains to be tested, for instance by employing an in vivo
knockdown approach, whether the miRNA candidates identified
here causally contribute to the therapeutic effects of fluoxetine
or not.
All in all, this study is the first that examined miRNA pro-
files in connection with PTSD and represents a promising starting
point for further evaluation of the role of miRNAs in PTSD
pathobiology.
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